Cite
HARVARD Citation
Petrylak, D. et al. (2017). Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial. Lancet. 390 (10109), pp. 2266-2277. [Online].